Copy number architectures define treatment-mediated selection of lethal prostate cancer clonesMore about Open Access at the Crick
Authors listAM Mahedi Hasan Paolo Cremaschi Daniel Wetterskog Anuradha Jayaram Stephen Q Wong Scott Williams Anupama Pasam Anna Trigos Blanca Trujillo Emily Grist Stefanie Friedrich Osvaldas Vainauskas Marina Parry Mazlina Ismail Wout Devlies Anna Wingate Mark Linch Cristina Naceur-Lombardelli PEACE consortium Charles Swanton Mariam Jamal-Hanjani Stefano Lise Shahneen Sandhu Gerhardt Attard
Despite initial responses to hormone treatment, metastatic prostate cancer invariably evolves to a lethal state. To characterize the intra-patient evolutionary relationships of metastases that evade treatment, we perform genome-wide copy number profiling and bespoke approaches targeting the androgen receptor (AR) on 167 metastatic regions from 11 organs harvested post-mortem from 10 men who died from prostate cancer. We identify diverse and patient-unique alterations clustering around the AR in metastases from every patient with evidence of independent acquisition of related genomic changes within an individual and, in some patients, the co-existence of AR-neutral clones. Using the genomic boundaries of pan-autosome copy number changes, we confirm a common clone of origin across metastases and diagnostic biopsies, and identified in individual patients, clusters of metastases occupied by dominant clones with diverged autosomal copy number alterations. These autosome-defined clusters are characterized by cluster-specific AR gene architectures, and in two index cases are topologically more congruent than by chance (p-values 3.07 × 10-8 and 6.4 × 10-4). Integration with anatomical sites suggests patterns of spread and points of genomic divergence. Here, we show that copy number boundaries identify treatment-selected clones with putatively distinct lethal trajectories.
Journal Nature Communications
Issue number 1